ANCN vs. ACRV, BRNS, ELYM, RFL, RMTI, ITRM, LVTX, FBLG, KZR, and FGEN
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Acrivon Therapeutics (ACRV), Barinthus Biotherapeutics (BRNS), Eliem Therapeutics (ELYM), Rafael (RFL), Rockwell Medical (RMTI), Iterum Therapeutics (ITRM), LAVA Therapeutics (LVTX), FibroBiologics (FBLG), Kezar Life Sciences (KZR), and FibroGen (FGEN). These companies are all part of the "medical" sector.
Anchiano Therapeutics vs.
Acrivon Therapeutics (NASDAQ:ACRV) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.
Anchiano Therapeutics' return on equity of 36.08% beat Acrivon Therapeutics' return on equity.
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Acrivon Therapeutics had 16 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 16 mentions for Acrivon Therapeutics and 0 mentions for Anchiano Therapeutics. Anchiano Therapeutics' average media sentiment score of 0.00 beat Acrivon Therapeutics' score of 0.00 indicating that Anchiano Therapeutics is being referred to more favorably in the news media.
Anchiano Therapeutics received 18 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 95.24% of users gave Acrivon Therapeutics an outperform vote while only 65.91% of users gave Anchiano Therapeutics an outperform vote.
Acrivon Therapeutics presently has a consensus target price of $17.71, suggesting a potential upside of 1,414.04%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Anchiano Therapeutics.
Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acrivon Therapeutics has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.
Summary
Acrivon Therapeutics beats Anchiano Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ANCN) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy ANCN Stock Free ANCN Stock Alerts